Global Interventional Pulmonology Market Key Vendor Analysis 2022

Posted by sandeep gade on December 5th, 2022

Interventional pulmonology is an area of pulmonary medicine that deals specifically with minimally invasive endoscopic and percutaneous procedures for the diagnosis and treatment of neoplastic as well as non-neoplastic diseases of the airways, lungs, and pleura. Rise in the number of COPD cases across the world is expected to boost demand over the coming years. Need for faster recovery time and reduced pain during procedures and surgeries for respiratory disorders has strengthened the market. Leading manufacturers of interventional pulmonology devices are focusing on geographical expansion to increase revenue and add new repair and service centers in emerging countries through the acquisition of local players.

Various awareness programs have been initiated by healthcare providers and health organizations/societies such as environmental programs, medication maintenance programs, and online education programs for public and healthcare professionals across the globe to control asthma, COPD, and other respiratory diseases. Major companies such as Boston Scientific Corporation, Olympus Corporation, and FUJIFILM Corporation, besides others, are focused on spreading awareness regarding respiratory diseases.

As per Persistence Market Research analysis, the global interventional pulmonology market is expected to exhibit a CAGR of more than 4% over the forecast period (2021 – 2031).

Key Takeaways from Study

IP diagnostic devices are expected to hold maximum revenue share under products.

Lung cancer is projected to be the dominant segment among indications, in terms of revenue. The segment accounted for 26.6% share in 2020.

The U.S., followed by Europe, is expected to hold substantial revenue share in the global interventional pulmonology market.

Emerging economies such as China, India, Brazil, Mexico, and South Africa have a large COPD patient pool, and rising disposable income of patients with increased healthcare expenditure would encourage interventional pulmonology device manufacturers to enter these markets.

The interventional pulmonology space faced adverse effects due to the COVID-19 crisis as a result of supply chain disruptions and economic impact of the pandemic on small- and medium-sized enterprises.

Hospitals and diagnostic centers to account for bulk of the market share (around ¾).

“Rising global prevalence of various respiratory diseases has increased demand for effective diagnosis and treatment in order to better manage the progression rate of these diseases,” says a Persistence Market Research analyst.

 Buy Full Report Now and Get Up to 20% Discount: https://www.persistencemarketresearch.com/checkout/12544